Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

By S. Halabi, E. Small, P. Kantoff, M. Kattan, E. Kaplan, N. Dawson, E. Levine, B. Blumenstein, N. Vogelzang. Journal of Clinical Oncology, 2003

706 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3683605437d7fb2cc4d9acaf2e243563cd1d3947

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Hans Lilja
2. Celestia S. Higano
3. M. Cheever

Citations in the corpus

• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (2010, neutral): “8 years for the control arm, but age is not a significant prognostic factor in prostate cancer.(14) None of the other baseline clinical parameters were different.”
• Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007, background): “Although it is a factor in a prognostic nomogram (13), baseline Gleason score was not predictive of overall survival in our study.”
• PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011, methodology): “The Halabi prognostic model can be used to predict individual survival probabilities of patients with metastatic hormone-refractory prostate cancer (17).”